RxDoctor Payments DataLook up a doctor →

Chad Hillyer, PA

Dermatology · Elkhorn, NENPI 1902825904

Payments from drug & device makers

$14,992in general payments, 2019–2025

Across 843 payments — averaging $17.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Lilly USA, LLC$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Amgen$1K
  • Johnson & Johnson$1K
  • Sun Pharmaceutical Industries Inc.$954
  • plus $7K from 23 others

What the payments were for

  • Food & beverage$14,40096%
  • Education$5924%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,992 in reported general payments places this provider in the 85th percentile of 68 dermatology providers in Nebraska.

See all dermatology providers in Nebraska

Medicare billing

Part B allowed, 2024
$152,416
Medicare patients
690
Services billed
3,351

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab20$302,378
OtezlaApremilast27$143,370
Dupixent SyringeDupilumab11$42,019
Clobetasol Propionate113$5,480
Triamcinolone Acetonide156$2,569
Doxycycline Hyclate46$2,540
Fluorouracil14$1,697
Minocycline Hcl33$801
Fluticasone Propionate26$596
Econazole Nitrate11$591
Hydroxyzine Hcl51$589
Fluconazole27$446
Ciclopirox14$407
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip17$379
Imiquimod12$319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$1,077$143,37027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 68 dermatology providers in Nebraska.

Other dermatology in Elkhorn

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →